Definitive clinical or radiologic evidence of metastatic disease; required imaging studies must have been performed within 90 days prior to randomization Clinical or radiographic evidence of metastatic disease; metastatic workup is not required, but is recommended for patients with clinical stage III disease; Note: isolated ipsilateral supraclavicular node involvement is permitted Definitive clinical or radiologic evidence of metastatic disease Definitive clinical or radiologic evidence of metastatic disease Definitive clinical or radiologic evidence of metastatic disease; no nodal involvement or evidence of metastatic disease allowed as defined by screening of the pelvis Definitive evidence of metastatic meningioma Known definitive clinical or radiologic evidence of metastatic disease Patients with evidence of metastatic disease involvement in viscera or bone Patients with evidence of myelodysplasia Evidence or high suspicion of metastatic disease at enrollment Definitive clinical or radiologic evidence of metastatic disease. No evidence of extrahepatic metastatic disease Histologic evidence of DDLS at any time prior to randomization AND current evidence of DDLS requiring treatment Definitive clinical or radiologic evidence of metastatic disease, as documented by the treating institution Pathologically proven, radiologic or clinical evidence of distant metastatic disease (this includes all disease below the clavicles, as well as disease metastatic to the bone, brain, or in the spinal canal) Patient has evidence of metastatic disease Evidence of metastatic disease TREATMENT WITH SJCAR19: Evidence of active, uncontrolled neurologic disease Has evidence of metastatic disease at time of diagnosis. Evidence of metastatic disease No evidence of metastatic disease as determined by imaging procedures. Documented evidence of active acromegaly Unequivocal evidence of metastatic disease defined by computerized tomography (CT) (includes resectable metastases) Evidence of metastatic disease. Clinically no evidence of local, regional, or metastatic disease at the time of study entry Clinical or radiologic evidence of local or regional recurrence of disease or metastatic disease prior to or at the time of study entry Clinically node negative, no evidence of metastatic disease Evidence of metastatic disease that is extensive enough to preclude consideration of subsequent definitive surgery for the primary tumor No evidence of hydronephrosis Evidence of disease by standard morphologic or by minimal residual disease (MRD) criteria Evidence of ischemic heart disease as determined by study cardiologist Evidence of metastatic disease Definitive clinical or radiologic evidence of metastatic disease; imaging must have been performed no greater than 30 days prior to initiation of chemotherapy Evidence of hemachromatosis. Evidence of metastatic disease on imaging studies performed at the discretion of their physician Evidence of metastatic disease No evidence of metastatic disease Any evidence of metastatic disease M0 stage based on no evidence of metastatic disease by CT imaging. Clinical evidence or known history of cardiopulmonary disease Evidence of metastatic disease Patients with clinical evidence of metastatic disease. Evidence of ischemic heart disease as determined by study cardiologist Prior evidence of 1p/19q co-deletion Patients with evidence of extraneural disease Patients with evidence of metastatic disease involvement in viscera or bone Definitive clinical or radiologic evidence of metastatic disease Patients must have evidence of metastatic disease (non measurable disease is eligible) Definitive clinical or radiologic evidence of metastatic disease or adenopathy below the clavicles Definitive clinical or radiologic evidence of metastatic disease; (chest imaging [mandatory for all patients] and other imaging [if required] must have been performed within 90 days prior to randomization) Patients with evidence of metastatic disease outside of the pelvis Evidence of metastatic disease outside of the abdomen Evidence of metastatic disease outside of the abdomen Current or previous evidence of muscle invasive (muscularis propria) or metastatic disease presented at the screening visit. Examples that increase the risk of metastatic disease are (but not limited to): Patient with documented evidence of metastatic disease Clinical or radiologic evidence of local or regional recurrence of disease or metastatic disease prior to or at the time of study entry No prior or present evidence of metastatic disease; Definitive clinical or radiologic evidence of progressive disease Clinical or radiographic evidence of metastatic disease; metastatic workup is not required\r\n* Note: isolated ipsilateral supraclavicular node involvement is permitted Evidence of extrauterine spread of disease on imaging or during surgical evaluation Definite evidence of metastatic disease There is no evidence of disease relapse at the time of screening, and minimal residual disease (MRD) is acceptable Evidence of metastatic disease Definitive clinical or radiologic evidence of metastatic disease. No evidence of disease at the time of registration, including no clinical concern for disease recurrence based on each of the following:\r\n* No evidence of disease by history and physical exam\r\n* Cancer antigen (CA)125 within normal limits\r\n* Computed tomography (CT) abdomen/pelvis demonstrating no radiological evidence of disease performed after completion of chemotherapy =< 28 days before entering study Evidence of metastatic disease Evidence of metastatic disease (stage M1) No evidence of disease by standard morphology; minimal residual disease or molecular evidence of disease will not exclude Currently have no clinical evidence of disease No evidence of extranodal metastatic disease Definitive clinical or radiologic evidence of metastatic disease; indeterminant lung nodules less than 8 mm are acceptable Resectable primary tumor with no evidence of metastatic disease by imaging. Imaging must be performed within 45 days of Day 1 of study. Evidence of extrauterine spread of disease on imaging or during surgical evaluation Definitive clinical or radiologic evidence of metastatic disease; pN3 disease is not allowed (positive common iliac node) Patients with only locally or regionally confined disease without evidence of metastatic disease No evidence of metastatic disease Has a prior history or current evidence of intracranial (CNS) metastatic RCC, except for ?3 lesions treated by CyberKnife or excisional surgery, clinically stable for at least 4 weeks, and without evidence of recurrence on MRI imaging at screening. Evidence of nephrectomy Clinical or radiologic evidence of distant metastatic disease other than small volume (<1.5 cm) nodes, this should be tested within 12 months from enrollment; Participants with evidence of non-hepatic metastatic disease Subjects who have clinical evidence of carcinoid-induced heart disease No evidence of known metastatic disease (M0 or Mx allowed) Evidence of encephalopathy within last 3 months Completely resected hepatic metastases without current evidence of other metastatic disease Patients with known primary or metastatic CNS disease (cohort B), are not eligible if they have a mini mental state exam score < 15 or evidence of leptomeningeal disease Evidence of metastatic disease on imaging studies Definitive clinical or radiologic evidence of metastatic disease; if applicable Definitive evidence of multifocal disease No evidence of disease Cancer survivor, with no evidence of active disease Clinical evidence of metastatic disease Have no current evidence of disease Survivors must not have evidence of recurrent or metastatic disease Evidence of complete response at three months post-treatment; maintenance therapy is permitted as long as there is no evidence of disease There is evidence of the disease at the time of entry into the trial Patients seen in the SCC with a diagnosis of cancer with or without evidence of metastatic disease No known evidence of disease Have no evidence of recurrence or metastatic disease Patients who currently have no evidence of disease Evidence of or treatment for metastatic disease Evidence of relapsed disease Patients must be without evidence of M0 Evidence of malignancy within 6 months of study enrollment; this is defined as clear morphologic, radiologic or molecular evidence of disease; mixed chimerism is allowed at the discretion of the clinician No evidence of residual disease on scan No evidence of disease metastatic to bone marrow. Clinical evidence of metastatic (T4b, any N; any T, N2-3; M1) disease Patients must be without evidence of residual disease as assessed by their treatment team No evidence of disease Patients must have evidence of disease either through elevation of tumor markers or radiologic evidence of disease No evidence of peritoneal disease on preoperative imaging Patients with a history of CRC without clear evidence of metastatic disease who have completed their acute cancer-specific treatment No evidence of metastatic disease Has no evidence of disease Serum lipase =< ULN at baseline; patients with glucose intolerance should be on a stable regimen and be monitored Serum lipase =< 1.5 x ULN Serum lipase =< 1.5 ULN Lipase: 1.5 x ULN. Subjects with lipase >1.5 x ULN may enrol if there are neither clinical or radiographic signs of pancreatitis Serum pancreatic lipase < 1.5 x ULN EXCLUSION - INFUSION: Lipase > 70 U/ml Serum lipase =< ULN Lipase =< 1 x ULN. Lipase =< 1.5 X institutional ULN Serum lipase > 1.5 x ULN Lipase =< 1.5 x ULN Serum lipase =< ULN Lipase =< 3 x ULN Lipase =< ULN Lipase < 2 ULN Serum lipase =< ULN CAPMATINIB INCLUSION CRITERIA: Serum lipase =< ULN Serum lipase =< ULN For patients being screened for Group 2: Serum lipase > ULN Serum lipase =< ULN Serum lipase =< 2 x ULN Serum lipase =< ULN Serum lipase > ULN Serum lipase =< ULN Lipase < ULN Lipase =< 1.5 x the ULN Within 14 days prior to registration: Serum lipase =< 1.5 x institution’s ULN Lipase > 1.5 ULN; participants with lipase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis Lipase < 1.5 times the ULN Fasting serum lipase =< institutional ULN Lipase =< 1.5 x ULN Serum lipase =< ULN Lipase =< 1.5 x the ULN Serum lipase =< ULN Lipase ? 1.5 x ULN Lipase =< 1.5 x the ULN Lipase less than or equal to 2 x ULN Lipase =< 1.5 x the ULN Serum lipase =< ULN Lipase =< 1.5 x the ULN PART B: Serum lipase =< 1.5 X ULN Serum lipase =< ULN Obtained =< 7 days prior to registration: Serum lipase =< 1.5 x ULN Serum lipase ? 2 x ULN Serum lipase =< 1.5 x ULN Lipase levels < 1.5 X ULN Serum lipase =< ULN Lipase =< 1.5 x the ULN Lipase ULN Serum lipase =< ULN Lipase =< 1.5 x the ULN >= grade 2 lipase increased (> 1.5 x ULN) Lipase =< 1.5 x ULN Serum lipase =< ULN Lipase =< 1.5 x the ULN Lipase =< 1.5 ULN Serum lipase =< 1.5 x ULN Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis, within 14 days before the first dose of cabozantinib Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis within 7 days before the first dose of cabozantinib Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis Obtained within 28 days prior to the first dose of cabozantinib: lipase =< 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis. Lipase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitis Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis Within 4 days prior to the first dose of cabozantinib: Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis Lipase < 2.0 x ULN; no radiologic or clinical evidence of pancreatitis Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis Within 7 days before the first dose of cabozantinib: Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis Lipase < 2.0 x ULN; no radiologic/clinical evidence of pancreatitis Lipase < 2 X the upper limit of normal (ULN) and no radiologic or clinical evidence of pancreatitis Lipase =< 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis Lipase and amylase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitis Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis Amylase and lipase =< 1.5 x ULN without any symptoms of pancreatitis Patients must have amylase or lipase within =< 1.5 x IULN without symptoms of pancreatitis at registration, within 28 days prior to registration Amylase/lipase =< 1.5 x institutional ULN (without symptoms of pancreatitis) Asymptomatic serum amylase =< grade 2 and asymptomatic serum lipase =< grade 2; patients with grade 1 or grade 2 serum amylase or lipase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.), at the screening visit History of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease. Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease Note: in the absence of clinical symptoms of pancreatitis, elevations of amylase or lipase are not contraindications to therapy on this trial History of pancreatitis or history of increased amylase or lipase that was due to pancreatitis CERITINIB EXCLUSION CRITERIA: History of pancreatitis, or history of increased amylase or lipase that was due to pancreatic disease Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease Lipase <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis. Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease Serum amylase or serum lipase CTCAE grade ? 1 with signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g. elevated P-amylase, abnormal imaging findings of pancreas, etc) Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease. History of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease History of pancreatitis, or amylase > ULN Patients with a prior or current history of a second malignancy, impaired GI function, history of pancreatitis or increased amylase or lipase, known diagnosis of HIV, and clinically significant cardiac disease were excluded. Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease Lipase <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis. Lipase ?1.5×ULN and amylase ?1.5×ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis. Lipase must be <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis and cholecystitis.